Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 10/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | PTPRC | P08575 | 2/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.65 |
| ▸ | PTPA | Q15257 | 2/20 | 0.65 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | PTPRF | P10586 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627300 | 0.86 | MAPT (0.72) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL3629109 | 0.86 | MAPT (0.72) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL13837643 | 0.85 | ANO1 (0.58) | ANO1PTPN1PTPRCPTPN2PTPA | |
| SCHEMBL13838015 | 0.85 | ANO1 (1.00) | ANO1ANO2 | |
| SCHEMBL3629702 | 0.84 | TP53 (0.82) | ANO1PTPN1PTPRCPTPN2PTPA | |
| SCHEMBL13837658 | 0.82 | PRKCZ (0.66) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL8289507 | 0.80 | PTPN1 (0.69) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL21247385 | 0.80 | TP53 (0.72) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL14123489 | 0.78 | PRKCZ (0.63) | PTPN1PTPRCPTPN2PTPATP53 | |
| SCHEMBL29059595 | 0.77 | ANO1 (1.00) | ANO1ANO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889672-B2 | Compounds, formulations, and methods of protein kinase C inhibition | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149452-A1 | COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | PRKCA, PRKCH, PRKCI | ANO1 1115/4885PTPN1 1256/4885PTPRC 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.